Poolbeg Pharma PLC POLB 001 Oncology Programme Update Meeting (9458R)
01 Noviembre 2023 - 1:00AM
UK Regulatory
TIDMPOLB
RNS Number : 9458R
Poolbeg Pharma PLC
01 November 2023
Poolbeg Pharma plc
Notice of POLB 001 Oncology Programme Update Meeting
1 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company targeting diseases with a high unmet medical need,
announces that it will host a meeting for investors and analysts on
the POLB 001 Oncology Programme on Monday 6 November 2023 at 2:00pm
- 3:30pm GMT via the Investor Meet Company platform .
The event will provide an update and greater detail on Poolbeg's
POLB 001 Oncology programme, which is targeting the Cytokine
Release Syndrome (CRS) associated with many cancer immunotherapy
treatments. Severe cases of CRS are life-threatening and may
require intensive supportive care, including mechanical
ventilation. An effective treatment for CRS has the potential to
make these cancer immunotherapies more accessible, while reducing
the potentially life-threatening side effects impacting patients
and healthcare systems worldwide.
The meeting will be led by Jeremy Skillington, PhD, Chief
Executive Officer, and will feature presentations from a number of
key opinion leaders and a patient advocate. The meeting will be
followed by a Q&A with the guest speakers and Poolbeg's senior
management.
Dr Martin Kaiser, team leader of the Myeloma Molecular Therapy
group at the Institute of Cancer Research and Honorary Consultant
Haematologist at The Royal Marsden NHS Foundation Trust
Presentation: Current innovations and future outlook in
immunotherapy in cancer. The challenges in safely and effectively
delivering these therapies to patients.
Bob Munroe, Myeloma Patient Advocate
Presentation: A patients' perspective: the need for broader
access to immunotherapies in cancer, through optimised side effect
management.
Professor Brendan Buckley, Scientific Advisory Board Member and
Honorary Clinical Professor at University College Cork and
University College Dublin
Presentation: POLB 001 as a potential treatment to manage
Cytokine Release Syndrome (CRS) associated with
onco-immunotherapies and other acute inflammatory conditions.
Registration
The presentation is open to all existing and potential
shareholders. Questions can be submitted in advance via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet for free and add Poolbeg
Pharma plc to their company dashboard via:
https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor
Investors who already follow Poolbeg on the Investor Meet
Company platform will automatically be invited.
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in infectious and other
prevalent diseases. Poolbeg Pharma has a disciplined portfolio
approach to mitigate risk, accelerate drug development, and enhance
investor returns. The Company simultaneously advances multiple
programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg Pharma also uses AI to interrogate human challenge trial
data sets to quickly identify new targets and drugs, leading to
faster development and greater commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025. Through opportunistic identification of assets
which complement Poolbeg Pharma's existing pipeline, the Company is
progressing programmes in oncology and metabolic syndromes; adding
disease areas with significant addressable markets.
With its initial assets from hVIVO plc , an industry leading
infectious disease and human challenge trials business, Poolbeg
Pharma has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction
in p38 MAP kinase driven cytokines in a clinical setting; a
first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine
candidate for Melioidosis (POLB 003). The Company is progressing
two A rtificial I ntelligence (AI) P rogrammes to add promising new
assets to its pipeline as well as developing an Oral Vaccine
Programme and an Oral Delivery Programme focussing on metabolic
syndrome related diseases.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUAARROVUROUA
(END) Dow Jones Newswires
November 01, 2023 03:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De May 2023 a May 2024